<div id="readability-page-1"><p>In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Vir Biotechnology, with a price target of <span id="expert-recommendation-target">$15.00</span>.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Aligos Therapeutics, and Vir Biotechnology. According to TipRanks, Trucchio has an average return of <span>35.2%</span> and a 56.03% success rate on recommended stocks. </p> <p>In addition to H.C. Wainwright, Vir Biotechnology also received a Buy from Needham’s Joseph Stringer in a report issued on December 8. However, on December 5, TR | OpenAI – 4o reiterated a Hold rating on Vir Biotechnology (NASDAQ: VIR).</p></div>

<p>H.C. Wainwright's Patrick Trucchio maintained a Buy rating on Vir Biotechnology with a $15.00 price target. Trucchio, who has a 35.2% average return and a 56.03% success rate, focuses on healthcare stocks. Needham’s Joseph Stringer also rated Vir Biotechnology a Buy, while another analyst reiterated a Hold rating.</p>

H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)